Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts

Abstract excerpt

Nilotinib, a second-generation tyrosine kinase inhibitor (TKI), has been described to be a superior drug in the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) [ 1 ]. However, with more mature follow-up, it has become clear that nilotinib is associated with impaired glucose and lipid metabolism [ 2 , 3 , 4 ] and an excess in arterial thrombotic events in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments
• Share to PI3K/AKT/mTOR signaling in cancer